Confident CAD management
starts with plaque quantification. 

Heartflow Plaque Staging* is
Backed by Evidence.

With outcomes from over 2,800 patients, Heartflow Plaque Staging* is the leading tool for patient risk stratification based on total plaque volume.1

Heartflow Plaque Staging*
Personalizes Individual Cardiac Risk

Heartflow Plaque Stage (mm3)
plaque staging chartgraph plaque mobile

† Controlling for risk factors, stenosis, and FFRCT.

Built for Action

Medical management recommendations developed by preventive cardiology and CCTA
expert consensus are currently being studied in the largest prospective registry of its kind.2

Overall considerations: Consider GLP1 treatment if BMI>27 | Lifestyle modifications guidance especially in higher stages.

Stage Total Plaque Volume LDL Goal Medical Management
Currently under clinical evaluation.
Mild‡ 1-100 <100
  • Statin
  • ± Aspirin
Moderate‡ >101-250 <70
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • ± Aspirin
  • If DM: Intensify therapy with GLP1 ± SGLT2I
Severe‡ >251-750 <55
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • Aspirin
  • Aggressive BP Rx
  • If DM: Intensify therapy with GLP1 ± SGLT2I
  • If elevated BMI: weight loss treatment
  • If elevated CRP & LDL at target: consider anti-inflammatories
Extensive <750 As low as can be achieved; at least <50
  • Same as severe
  • ± Colchicine ± Icosapent Ethyl

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

Driving Better Outcomes

For the first time, modeled outcomes show the risk of CV events could decrease when Heartflow Plaque Staging* guides care.4

14.9%

modeled relative reduction in major cardiac events compared to standard of care.